Decision-making in dyspepsia: Controversies in primary and secondary care

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 3, 1999, Pages 223-230

  Tytgat, G ^a   Hungin, A P S ^b   Malfertheiner, P ^c   Talley, N ^d   Hongo, M ^e   McColl, K ^f   Soule, J C ^g   Agreus L ^h   Bianchi Porro, G ⁱ   Freston, J ^j   Hunt, R ^k  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Health Centre   (United Kingdom)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF SYDNEY   (Australia)

^e TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f WESTERN INFIRMARY   (United Kingdom)

^g HÔPITAL LOUIS MOURIER   (France)

^h Vårdcentralen   (Sweden)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^k MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIULCER AGENT;

ABDOMINAL PAIN; DYSPEPSIA; ESOPHAGUS PH; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL REFLUX; HELICOBACTER PYLORI; HUMAN; MEDICAL DECISION MAKING; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SYMPTOM;

EID: 0033033633     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199903000-00003     Document Type: Review

References (76)

1. Talley NJ, Colin-Jones D, Koch KJ, Koch M, Nyren O, Stanhellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4:145-160.
2. Scolapio JS, Camilleri M. Nonulcer dyspepsia. Gastroenterologist 1996; 4:13-23.
3. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126:280-291.
4. Agreus L, Talley N. Challenges in managing dyspepsia in general practice. BMJ 1997; 315:1284-1288.
5. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110:72-83.
6. Talley NJ. Modern management of dyspepsia. Aust Fam Phys 1996; 25:47-52.
7. Jones RH, Lydeard SE, Hobbs FRD, Kenkre JE, Williams EL, Jones SJ, et al. Dyspepsia in England and Scotland. Gut 1990; 31:401-405.
8. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102:1259-1268.
9. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996; 10:83-89.
10. Brown C, Rees WDW. Dyspepsia in general practice. Try empirical treatment first and investigate patients who do not respond. BMJ 1990; 300:829-830.
11. Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1995; 30(suppl 211):35-38.
12. Colin-Jones DG. Management of dyspepsia: report of a working party. Lancet 1988; i:576-578.
13. Cann PA, Gleeson MH. Assessing dyspepsia in general practice. Br J Clin Pract 1994; 48:263-267.
14. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105:1378-1386.
15. Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997; 92:954-959.
16. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304:87-90.
17. Johannessen T, Petersen H, Kristensen P, Kleveland PM, Dybdahl J, Sandvik AK, et al. The intensity and variability of symptoms in dyspepsia. Scand J Primary Health Care 1993; 11:50-55.
18. Malagelada J-R. Functional dyspepsia. Insights on mechanisms and management strategies. Gastroenterol Clin N Am 1996; 25:103-112.
19. Small PK, Loudon MA, Waldron B, Smith D, Campbell FC. Importance of reflux symptoms in functional dyspepsia. Gut 1995; 36:189-192.
20. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastrooesophageal reflux disease. Lancet 1990; 335:205-208.
21. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study on Olmsted County, Minnesota. Gastroenterology 1997; 112:1448-1456.
22. Bolin TD, Tytgat NJ. Dyspepsia and esophageal reflux: an overview. Scand J Gastroenterol 1995; 30(suppl 210);43-44.
23. Fass R, Fennerty MB, Yalam JM, et al. Evaluation of the 'omeprazole test' in patients with typical symptoms of gastroesophageal reflux disease [Abstract]. Gastroenterology 1997; 112:A114.
24. Johannessen T. Petersen H, Kleveland PM, Dybdahl JH, Sandvik AK, Brenna E, et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990; 25:689-697.
25. Kang JY, Ho KY, Yeoh KG, Guan R. Chronic upper abdominal pain due to duodenal ulcer and other functional causes: its localization and nocturnal occurrence. J Gastroenterol Hepatol 1996; 11:515-519.
26. Holdstock G, Harman M, Machin D, Patel C, Lloyd RS. Prospective testing of a scoring system designed to improve case selection for upper gastro- intestinal investigation. Gastroenterology 1986; 90:1164-1169.
27. Mann J, Holdstock G, Harman M, Machin D, Loehry CA. Scoring system to improve cost-effectiveness of open access endoscopy. BMJ 1983; 287:937-940.
28. Talley NJ, McNeil D, Piper DW. Discriminant value of dyspeptic symptoms: a study of the clinical presentation of 221 patients with dyspepsia of unknown cause, peptic ulceration, and cholelithiasis. Gut 1987; 28:40-46.
29. Hungin APS, Rubin GP, O'Flanagan H. Long term prescribing of proton pump inhibitors in general practice: clinical and cost implications [Abstract]. Gastroenterology 1997; 112(suppl):19; Hungin APS, Bramble MG, Idle N. Is it possible to diagnose dyspepsia accurately in general practice? [Abstract]. Gut 1997; 40(suppl 1):A60.
30. Hungin APS, Rubin GP, O'Flanagan H. Long term prescribing of proton pump inhibitors in general practice: clinical and cost implications [Abstract]. Gastroenterology 1997; 112(suppl):19; Hungin APS, Bramble MG, Idle N. Is it possible to diagnose dyspepsia accurately in general practice? [Abstract]. Gut 1997; 40(suppl 1):A60.
31. Chiba N, De Gara CJ, Wilkinson JM. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798-1810.
32. Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign oesophageal stricture. Gastroenterology 1994; 107:1545-1548.
33. Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11:541-546.
34. Euler AR, Murdock RH, Wilson TH. Ranitidine is effective in healing erosive esophagitis [Abstract]. Gastroenterology 1991; 100:A61.
35. 2-receptor antagonists. Aliment Pharmacol Ther 1990; 4:145-156.
36. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux esophagitis. Aliment Pharmacol Ther 1996; 10:529-539.
37. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161-167.
38. Hillman AL. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 29:98-102.
39. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907-915.
40. Mansi C, Savarino V, Mela GS, Celle G. Optimum timing for endoscopy in management of dyspepsia. Lancet 1994; 343:1501-1502.
41. Rune SJ. Better definition of endoscopy negative acid reflux disease. Aliment Pharmacol Ther 1997; 11(suppl 2);81-86.
42. Smout AJPM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997; 11(suppl 2):81-86.
43. Jones RH. Clinical economics review: gastrointestinal disease in primary care. Aliment Pharmacol Ther 1996; 10:233-239.
44. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994; 69:867-876.
45. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(suppl 1):24-29.
46. Spechler SJ. Barrett's esophagus. Gastroenterologist 1994; 2:273-284.
47. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315:362.
48. Cooper GS. Indications and contraindications for upper gastrointestinal endoscopy. Gastrointest Endosc Clin N Am 1994; 4:439-454.
49. Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Medical treatment of peptic ulcers. Practice guidelines. (Consensus statement.) JAMA 1996; 275:622-629.
50. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omoprazole. Gastroenterology 1988; 95:903-912.
51. Williams S. Weinman J. Dale J, Newman S. Patient expectations: what do primary care patients want from the GP and how far does meeting expectations affect patient satisfaction? Fam Pract 1995; 12:193-201.
52. 2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343:811-816.
53. Bramble MG. Open access endoscopy - a nationwide survey of current practice. Gut 1992; 33:282-285.
54. Peura DA, Graham DY. Helicobacter pylori: consensus reached; peptic ulcer is on the way to becoming a historic disease. Am J Gastroenterol 1994; 89:1137-1139.
55. National Institutes of Health. Helicobacter pylori in peptic ulcer disease. NIH Consensus Statement 1994; 12:1-22.
56. Collins JSA, Bamford KB, Sloan JM, Collins BJ, Moorehead RJ, Love AHG. Screening for Helicobacter pylori antibody could reduce endoscopy workload in young dyspeptic patients. Eur J Gastroenterol Hepatol 1992; 4:991-993.
57. McColl KEL, el-Nujumi A, Murray L, el-Omar E, Gillen D, Dickson A, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1997; 40:301-306.
58. Graham DY, Lew GM, Evans DG, Evans DJ Jr, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann Intern Med 1991; 115:266-269.
59. Penston JG. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8:369-389.
60. Hobbs FDR, Delaney BC, Rowsby M, Kenkre JE. Effect of Helicobacter pylori eradication therapy on dyspeptic symptoms in primary care. Fam Pract 1996; 13:225-228.
61. Stolte M. Helicobacter pylori and gastric MALT lymphoma. Lancet 1992; 339:745-756.
62. Wotherspoon AC, Doglioni C, Diss C, Pan L, Moschini A, de Boni M, et al. Regression of primary low grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575-577.
63. Velhuyzen van Zanten SO, Sherman PM. Indications for treatment of Helicobacter pylori infection: a systematic review. Can Med Assoc J 1994; 150:189-198.
64. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995; 123:260-268.
65. Tait CL, Jones RH. Helicobacter pylori: a test and treat strategy in primary care [Abstract]. Gut 1997; 40(suppl 1):F231.
66. Vakil N, Puetz T. One year outcome of a test and treat strategy for H. pylori infection in dyspeptic patients [Abstract]. Gastroenterology 1997; 112(suppl):A319.
67. Laheij RJ, Jansen JB, van de Lisdonk EH, Severens JL, Verbeek ALM. Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1996; 10:843-850.
68. Talley NJ. A critique of therapeutic trials in Helicobacter pylori positive functional dyspepsia. Gastroenterology 1994; 106:1174-1183.
69. Penston JG, Mistry KR. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther 1996; 10:139-145.
70. Lim AG, Martin RM, Montileone M, Walker AC, Gould SR. Helicobacter pylori serology and the management of young dyspeptics: a UK survey of gastroenterologists and general practitioners with an interest in gastroenter- ology. Aliment Pharmacol Ther 1997; 11:299-303.
71. Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD, et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995; 346:1315-1318.
72. Briggs AH, Sculpher MJ, Logan RPH, Aldous J, Ramsey ME, Baron JH. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996; 312:1321-1325.
73. Lind T, Van Zanten SV, Unge P, et al. Eradication of H. pylori using one- week triple therapies combining omeprazole with 2 antimicrobials: the MACH 1 study. Helicobacter 1996; 1:138-144.
74. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43:223-243.
75. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, et al. One week triple therapy for H. pylori: a multicentre comparative study. Gut 1997; 41:735-739.
76. Lind T, Bardhan KD, Bayerdarffer E, et al. The MACH 2 study: optimal H. pylori therapy needs omeprazole and can be reliably assessed by UBT [Abstract]. Gastroenterology 1997; 112(suppl):A200.